Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAV-240 in Moderate-to-Severe Hidradenitis Suppurativa
NCT07384975Phase 2Recruiting
- Sponsor
- Navigator Medicines
- Start
- Jan 2026
- Primary completion
- Sep 2027
- Modality
- Bispecific Antibodies
- Countries
- 8
01
Overview
A Phase 2 trial of NAV-240 in hidradenitis suppurativa (HS), sponsored by Navigator Medicines. Started Jan 2026; status: recruiting.
02
Drugs
NAV-240
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT07384975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07384975.